Assessing the results: Phase 1 hyperlipidemia outcomes in 27 health plans

Latts, Lisa

doi:10.1016/s0002-9343(01)00674-x

Cited by 26 publications

(16 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 -18 Patients with diabetes taking a lipid-lowering drug were more than 3 times as likely to have achieved the LDL goal specified by the ADA. Previous studies, however, have found that even among patients using a lipid-lowering drug, many do not achieve the LDL cholesterol goal 19,20 ; in one study, the majority of patients who were currently using a lipid-lowering drug had not achieved goal. 21 In almost all cases, patients were not taking the maximum drug dose, suggesting that inadequate dosing may be one explanation for failure to achieve goal.…”

Section: Discussionmentioning

confidence: 89%

Compliance with Recommendations for Lipid Management among Patients with Type 2 Diabetes in an Academic Family Practice

Putzer

Roetzheim²,

Ramirez³

et al. 2004

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

Background: Lipid abnormalities are twice as common in patients with type 2 diabetes, and this contributes substantially to their increased risk of cardiac disease. The American Diabetic Association (ADA) has defined treatment goals for high-density lipoprotein (HDL) cholesterol (>45 mg/dL), triglyceride (<200 mg/dL), and low-density lipoprotein (LDL) cholesterol (<100 mg/dL). It is unknown, however, how frequently patients with diabetes managed in primary care settings are able to attain these treatment goals.Methods: We randomly selected 239 patients with type 2 diabetes and conducted a chart review to determine whether patients had attained ADA lipid goals. We examined clinical predictors of goal attainment using logistic regression.Results Conclusion: We found that the majority of patients with diabetes failed to attain lipid goals set forth by the American Diabetes Association. Further study is needed in larger populations to confirm these findings, and if confirmed, to determine the reasons that patients fail to achieve lipid goals. (J Am

show abstract

Section: Discussionmentioning

confidence: 89%

Compliance with Recommendations for Lipid Management among Patients with Type 2 Diabetes in an Academic Family Practice

Putzer

Roetzheim²,

Ramirez³

et al. 2004

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

show abstract

“…Another possible reason is physician non-compliance with the recommended titration schedule. The failure to titrate lipid-modifying drugs has been well-documented with statins [13][14][15] , which are very well-tolerated by patients. Since lipid levels were not reported either before or after ER niacin treatment, it is not clear whether or not physicians were titrating to target lipid levels.…”

Section: Discussionmentioning

confidence: 99%

Dosage, titration, and gaps in treatment with extended release niacin in clinical practice

Kamal-Bahl

Burke

Watson

et al. 2008

Current Medical Research and Opinion

View full text Add to dashboard Cite

A considerable proportion of new ER niacin users failed to reach recommended daily maintenance dosages in clinical practice. The main limitations of the study include its reliance on administrative data, inability to capture over-the-counter niacin use, and evaluation of reasons for suboptimal titration. Future research should determine the extent to which gaps in ER niacin therapy and failure to titrate to optimal dosages are due to poor tolerability, physician practice, or other factors.

show abstract

“…22 The author reported LDL-C goal attainment in 87% of low-risk primaryprevention patients, 65% of high-risk primary-prevention patients, and 44% of combined secondaryprevention and diabetes patients. However, patients were included in the study only if they were currently being managed with statin therapy.…”

Section: No (%) Patients At Goal No Patients Characteristicmentioning

confidence: 99%